Shire preparing for all outcomes as it awaits lifitegrast approval
This article was originally published in Scrip
Executive Summary
Although Shire strived to place its flat earnings during the second quarter into a positive context on 23 July, its second quarter earnings call largely focused on dry eye disease candidate lifitegrast and how the US FDA might view the mixed data from its pivotal Phase III studies.